Please login to the form below

Not currently logged in
Email:
Password:

pegaspargase

This page shows the latest pegaspargase news and features for those working in and with pharma, biotech and healthcare.

SMC approves Opdivo combo as first-line skin cancer treatment

SMC approves Opdivo combo as first-line skin cancer treatment

The regulator also accepted Baxalta's Oncaspar (pegaspargase) for NHS use, approving the drug as part of an antineoplastic combination therapy for paediatric and adult patients with acute lymphoblastic leukaemia.

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Pfenex is a biosimilars company, and the agreement with Jazz also includes rights to a recombinant pegaspargase candidate.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics